CRISPR Therapeutics Faces Significant Challenges Amid Slow Rollout
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Should l Buy CRSP?
Source: NASDAQ.COM
- Escalating Financial Losses: CRISPR reported a net loss exceeding $580 million in 2025, a significant increase from the $366.3 million loss in 2024, highlighting the pressure from high expenditures during the rollout of the Casgevy treatment and ongoing financial struggles.
- Strong Cash Position: Despite the losses, CRISPR maintained approximately $2 billion in cash and marketable securities at the end of last year, which is sufficient to support its daily operations, having consumed $345 million in 2025, indicating that the company is not at immediate risk of running out of funds.
- Slow Product Rollout: Although Casgevy was approved in 2023 and patient initiations nearly tripled last year, its staggering price of $2.2 million and profit-sharing with Vertex Pharmaceuticals limit CRISPR's market earnings, adversely affecting its profitability.
- Uncertain Market Outlook: While CRISPR's gene-editing therapies hold long-term potential, the lack of current profitability and the risk assessment of its stock make it a cautious buy for investors, especially as it was not included in the list of top recommended stocks by analysts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRSP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRSP
Wall Street analysts forecast CRSP stock price to rise
10 Analyst Rating
8 Buy
2 Hold
0 Sell
Strong Buy
Current: 46.950
Low
50.00
Averages
78.89
High
105.00
Current: 46.950
Low
50.00
Averages
78.89
High
105.00
About CRSP
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
CRISPR Therapeutics Faces Challenges and Opportunities Ahead
- Poor Drug Launch Performance: Despite CRISPR Therapeutics receiving approval for its first commercial drug, Casgevy, in 2023, the market performance has not significantly boosted the stock price, with total revenue plummeting to $3.5 million in 2025 from $37.3 million in 2024, indicating insufficient market acceptance.
- High Treatment Costs: Casgevy's treatment costs $2.2 million and its complex administration process complicates partnerships with insurers and qualified treatment centers, resulting in limited profits for CRISPR, which shares a 40%-60% revenue split with Vertex Pharmaceuticals, exacerbating financial pressures.
- Slow Clinical Progress: CRISPR Therapeutics has failed to achieve sufficient clinical progress over the past few years to impress investors, with occasional positive results but overall lacking breakthrough advancements, leading to a continued decline in stock price, with net loss per share worsening to $6.47 in 2025.
- Future Potential to Explore: Despite challenges, CRISPR Therapeutics has several promising candidates in its pipeline, such as CTX310 and SRSD107, which, if successfully advanced, could improve the company's market outlook over the next 5 to 10 years, attracting attention from investors with above-average risk tolerance.
See More
CRISPR Therapeutics Faces Challenges and Opportunities Ahead
- Poor Revenue Performance: CRISPR Therapeutics' first approved product, Casgevy, generated only $3.5 million in revenue in 2025, a significant drop from $37.3 million in 2024, indicating limited market acceptance despite its approval, which adversely affects the company's overall financial health.
- Slow Clinical Progress: The company has struggled with clinical advancements in recent years, and while promising candidates like CTX310 and SRSD107 show potential, the lack of sufficient clinical results has undermined investor confidence, leading to a continued decline in stock price.
- Revenue Dependency on Partnerships: Casgevy's sales revenue heavily relies on collaboration with Vertex Pharmaceuticals, with CRISPR sharing 40% of the profits, which constrains its profitability and exacerbates financial pressures on the company.
- Future Potential to Explore: Despite numerous challenges, Casgevy generated $116 million in revenue in 2024, and several of CRISPR's candidates, such as CTX310, could achieve breakthroughs in the coming years, potentially providing substantial market opportunities if successfully launched.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: ARKK ETF's 52-week low is $38.5686 per share and high is $92.65, with the latest trade at $69.69, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify notable inflows (new units created) or outflows (old units destroyed), which can affect the individual components held within ETFs and subsequently influence overall market performance.
See More
CRISPR Therapeutics Prices $550 Million Convertible Notes Offering
- Upsized Offering: CRISPR Therapeutics announced the pricing of $550 million in convertible senior notes, an increase from the previously announced $350 million, indicating strong market demand for its financing needs.
- Investor Option: The company granted initial purchasers an option to buy an additional $50 million, which not only enhances investor participation but also potentially increases the flexibility of the company's financing strategy.
- Conversion Rate: The initial conversion rate is set at 13.0617 common shares per $1,000 principal amount of notes, providing investors with a potential equity appreciation opportunity that may attract more institutional interest.
- Clear Use of Proceeds: The net proceeds from this offering will be used for general corporate purposes and are expected to close on March 16, providing essential funding support for the company's operations and future growth.
See More
CRISPR Therapeutics Prices $550M Convertible Notes Offering
- Increased Financing Size: CRISPR Therapeutics upsized its planned $350M convertible notes offering to $550M, reflecting strong market demand and providing the company with enhanced financial resources for future initiatives.
- Additional Purchase Option: Buyers have the option to purchase an additional $50M of notes within 13 days of issuance, which not only increases investor engagement but also has the potential to further boost the total financing amount for the company.
- Interest Rate and Conversion Terms: The notes carry an effective coupon of 1.125%, with an initial conversion price of approximately $76.56 per share, representing a 45% premium over the last reported price, indicating the company's confidence in future stock performance while offering investors potential capital appreciation.
- Clear Use of Proceeds: The company expects to raise about $536.3M in net proceeds from the offering, or $585.2M if the additional purchase option is fully exercised, with funds allocated for general corporate purposes to support strategic growth and operational needs.
See More
ARK Invest Increases Stake in CRISPR Therapeutics Amid Market Volatility
- Increased Stake in Gene Editing: ARK Invest purchased 280,609 shares of CRISPR Therapeutics (NASDAQ:CRSP) worth approximately $14.82 million, following a 10% drop in the stock due to a $350 million private offering, indicating confidence in the company's long-term potential.
- Portfolio Rebalancing Strategy: Concurrently, ARK trimmed positions in related firms, offloading 78,412 shares of 10x Genomics (TXG) for about $1.60 million and 21,505 shares of Teradyne (TER) for $6.47 million, reflecting its rebalancing strategy across actively managed ETFs.
- Portfolio Weighting: CRISPR Therapeutics is the second-largest holding in ARK's ETFs, with a portfolio weight of 4.49% and total exposure of around $500 million, underscoring the company's significance and growth opportunities within ARK's investment strategy.
- Market Analysis Ratings: CRISPR Therapeutics has received a 'Buy' rating from Seeking Alpha due to its strong cash position and high growth potential, despite significant risks, with Wall Street analysts also rating the stock as 'Buy', indicating optimistic market expectations for its future performance.
See More
CRISPR Therapeutics Faces Challenges and Opportunities Ahead
- Poor Drug Launch Performance: Despite CRISPR Therapeutics receiving approval for its first commercial drug, Casgevy, in 2023, the market performance has not significantly boosted the stock price, with total revenue plummeting to $3.5 million in 2025 from $37.3 million in 2024, indicating insufficient market acceptance.
- High Treatment Costs: Casgevy's treatment costs $2.2 million and its complex administration process complicates partnerships with insurers and qualified treatment centers, resulting in limited profits for CRISPR, which shares a 40%-60% revenue split with Vertex Pharmaceuticals, exacerbating financial pressures.
- Slow Clinical Progress: CRISPR Therapeutics has failed to achieve sufficient clinical progress over the past few years to impress investors, with occasional positive results but overall lacking breakthrough advancements, leading to a continued decline in stock price, with net loss per share worsening to $6.47 in 2025.
- Future Potential to Explore: Despite challenges, CRISPR Therapeutics has several promising candidates in its pipeline, such as CTX310 and SRSD107, which, if successfully advanced, could improve the company's market outlook over the next 5 to 10 years, attracting attention from investors with above-average risk tolerance.
See More
CRISPR Therapeutics Faces Challenges and Opportunities Ahead
- Poor Revenue Performance: CRISPR Therapeutics' first approved product, Casgevy, generated only $3.5 million in revenue in 2025, a significant drop from $37.3 million in 2024, indicating limited market acceptance despite its approval, which adversely affects the company's overall financial health.
- Slow Clinical Progress: The company has struggled with clinical advancements in recent years, and while promising candidates like CTX310 and SRSD107 show potential, the lack of sufficient clinical results has undermined investor confidence, leading to a continued decline in stock price.
- Revenue Dependency on Partnerships: Casgevy's sales revenue heavily relies on collaboration with Vertex Pharmaceuticals, with CRISPR sharing 40% of the profits, which constrains its profitability and exacerbates financial pressures on the company.
- Future Potential to Explore: Despite numerous challenges, Casgevy generated $116 million in revenue in 2024, and several of CRISPR's candidates, such as CTX310, could achieve breakthroughs in the coming years, potentially providing substantial market opportunities if successfully launched.
See More
Analysis of ARKK ETF's 52-Week Price Fluctuations
- Price Range Analysis: ARKK ETF's 52-week low is $38.5686 per share and high is $92.65, with the latest trade at $69.69, indicating significant volatility over the past year that could influence investor decisions and market sentiment.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average provides valuable insights for investors, helping them assess market trends and potential buy or sell opportunities.
- ETF Trading Mechanism: Exchange-traded funds (ETFs) trade like stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the fund's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify notable inflows (new units created) or outflows (old units destroyed), which can affect the individual components held within ETFs and subsequently influence overall market performance.
See More
CRISPR Therapeutics Prices $550 Million Convertible Notes Offering
- Upsized Offering: CRISPR Therapeutics announced the pricing of $550 million in convertible senior notes, an increase from the previously announced $350 million, indicating strong market demand for its financing needs.
- Investor Option: The company granted initial purchasers an option to buy an additional $50 million, which not only enhances investor participation but also potentially increases the flexibility of the company's financing strategy.
- Conversion Rate: The initial conversion rate is set at 13.0617 common shares per $1,000 principal amount of notes, providing investors with a potential equity appreciation opportunity that may attract more institutional interest.
- Clear Use of Proceeds: The net proceeds from this offering will be used for general corporate purposes and are expected to close on March 16, providing essential funding support for the company's operations and future growth.
See More
CRISPR Therapeutics Prices $550M Convertible Notes Offering
- Increased Financing Size: CRISPR Therapeutics upsized its planned $350M convertible notes offering to $550M, reflecting strong market demand and providing the company with enhanced financial resources for future initiatives.
- Additional Purchase Option: Buyers have the option to purchase an additional $50M of notes within 13 days of issuance, which not only increases investor engagement but also has the potential to further boost the total financing amount for the company.
- Interest Rate and Conversion Terms: The notes carry an effective coupon of 1.125%, with an initial conversion price of approximately $76.56 per share, representing a 45% premium over the last reported price, indicating the company's confidence in future stock performance while offering investors potential capital appreciation.
- Clear Use of Proceeds: The company expects to raise about $536.3M in net proceeds from the offering, or $585.2M if the additional purchase option is fully exercised, with funds allocated for general corporate purposes to support strategic growth and operational needs.
See More
ARK Invest Increases Stake in CRISPR Therapeutics Amid Market Volatility
- Increased Stake in Gene Editing: ARK Invest purchased 280,609 shares of CRISPR Therapeutics (NASDAQ:CRSP) worth approximately $14.82 million, following a 10% drop in the stock due to a $350 million private offering, indicating confidence in the company's long-term potential.
- Portfolio Rebalancing Strategy: Concurrently, ARK trimmed positions in related firms, offloading 78,412 shares of 10x Genomics (TXG) for about $1.60 million and 21,505 shares of Teradyne (TER) for $6.47 million, reflecting its rebalancing strategy across actively managed ETFs.
- Portfolio Weighting: CRISPR Therapeutics is the second-largest holding in ARK's ETFs, with a portfolio weight of 4.49% and total exposure of around $500 million, underscoring the company's significance and growth opportunities within ARK's investment strategy.
- Market Analysis Ratings: CRISPR Therapeutics has received a 'Buy' rating from Seeking Alpha due to its strong cash position and high growth potential, despite significant risks, with Wall Street analysts also rating the stock as 'Buy', indicating optimistic market expectations for its future performance.
See More
